Opinion|Videos|June 11, 2024
MAJIC-PV Trial: Ruxolitinib vs Best Available Therapy in Hydroxyurea-Resistant/Intolerant Polycythemia Vera
With their final discussion the panel examines the survival outcomes and risk of thromboembolic/hemorrhagic events from the MAJIC-PV trial, which compared ruxolitinib to best available therapy in polycythemia vera patients resistant or intolerant to hydroxyurea.
Advertisement
Episodes in this series
Advertisement
Related to this article
Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Resection with cesium-131 tile-based radiation therapy prolonged time to surgical bed recurrence vs resection with stereotactic radiation in the phase 3 ROADS trial.
Degevma was approved for skeletal-related events in adults with bone metastases, giant cell tumor of bone, and the treatment of hypercalcemia of malignancy.
FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.
September brought accelerated approvals in ESR1-mutant breast cancer and HER2-mutant non–small cell lung cancer, a Galleri panel vote, and a withdrawn I-DXd application.
The application is supported by the phase 3 SAFFRON trial, in which savolitinib plus osimertinib improved progression-free and overall survival vs chemotherapy.
Proton therapy did not improve overall survival vs photon therapy in advanced hepatocellular carcinoma in the phase 3 NRG-GI003 trial.
Published findings from the ASPEN-06 trial of evorpacept in previously treated HER2+ gastric cancers included exploratory analyses suggesting CD47 is a predictive biomarker for benefit with the targeted agent.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
2
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
3
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
4
Denosumab Biosimilar Approved For Existing Oncology Indications
5